{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:30:01Z","timestamp":1790371801042,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jceh.2021.08.023","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T11:35:33Z","timestamp":1630064133000},"page":"144-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-4148","authenticated-orcid":false,"given":"Madhumita","family":"Premkumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh K.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2021.08.023_bib1","unstructured":"World Health Organization. Hepatitis B factsheet. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b Last accessed 14th February 2021."},{"issue":"suppl 2","key":"10.1016\/j.jceh.2021.08.023_bib2","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1136\/gut.38.Suppl_2.S56","article-title":"Epidemiology of hepatitis B virus infection in India","volume":"38","author":"Tandon","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.023_bib3","series-title":"Global Hepatitis Report 2017","year":"2017"},{"key":"10.1016\/j.jceh.2021.08.023_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2021.08.023_bib6","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jceh.2021.08.023_bib8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","article-title":"High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B","volume":"67","author":"Kim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.023_bib9","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.24442","article-title":"Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program","volume":"54","author":"McMahon","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib10","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cld.978","article-title":"Hepatitis C virus elimination by 2030: conquering mount improbable","volume":"16","author":"Dhiman","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2021.08.023_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/liv.13625","article-title":"How to control highly endemic hepatitis B in Asia","volume":"38","author":"Shan","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2021.08.023_bib12","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1186\/s12889-019-7534-2","article-title":"Hepatitis B vaccination coverage across India: exploring the spatial heterogeneity and contextual determinants","volume":"19","author":"Khan","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jceh.2021.08.023_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"Liu","year":"2019","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jceh.2021.08.023_bib14","series-title":"Global Health Sector Strategy on Viral Hepatitis 2016\u20132021","year":"2016"},{"key":"10.1016\/j.jceh.2021.08.023_bib15","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Tr\u00e9po","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2021.08.023_bib16","doi-asserted-by":"crossref","first-page":"e02007","DOI":"10.1128\/JVI.02007-17","article-title":"Hepatitis B virus DNA integration occurs early in the viral life cycle in an in\u00a0vitro infection model via sodium taurocholate cotransporting polypeptide-dependent uptake of enveloped virus particles","volume":"92","author":"Tu","year":"2018","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.jceh.2021.08.023_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gutjnl-2013-306228","article-title":"Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas","volume":"64","author":"Amaddeo","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.023_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jceh.2018.06.010","article-title":"INASL guidelines on management of hepatitis B virus infection in patients receiving chemotherapy, biologicals, immunosupressants, or corticosteroids","volume":"8","author":"Arora","year":"2018","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2021.08.023_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","volume":"59","author":"Sokal","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib21","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/gast.2001.24839","article-title":"Management of hepatitis B: 2000--summary of a workshop","volume":"120","author":"Lok","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.023_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.023_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/v9050096","article-title":"Immune tolerant chronic hepatitis B: the unrecognized risks","volume":"9","author":"Kennedy","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.jceh.2021.08.023_bib24","first-page":"274","article-title":"Incidence of hepatocellular carcinoma among Indian patients with cirrhosis of liver: an experience from a tertiary care center in northern India","volume":"26","author":"Paul","year":"2007","journal-title":"Indian J Gastroenterol"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2021.08.023_bib25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jceh.2014.05.013","article-title":"Epidemiology of hepatocellular carcinoma in India","volume":"4","author":"Acharya","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"suppl 3","key":"10.1016\/j.jceh.2021.08.023_bib26","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jceh.2014.02.155","article-title":"Risk factors for hepatocellular carcinoma in India","volume":"4","author":"Kar","year":"2014","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib27","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","article-title":"Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients","volume":"70","author":"Testoni","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib28","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum hepatitis B virus RNA: a new potential biomarker for chronic hepatitis B virus infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3350\/cmh.2018.0040","article-title":"Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib30","first-page":"767","article-title":"Liver sampling: a vital window into HBV pathogenesis on the path to functional cure","volume":"67","author":"Gill","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.023_bib31","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/hep.23424","article-title":"Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage","volume":"51","author":"Wu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1053\/j.gastro.2008.02.075","article-title":"Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT","volume":"134","author":"Kumar","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.023_bib33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jhep.2006.03.007","article-title":"F\u00e9d\u00e9ration nationale des P\u00f4les de r\u00e9f\u00e9rence et des R\u00e9seaux H\u00e9patites. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases","volume":"45","author":"Zarski","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib34","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cgh.2007.01.005","article-title":"Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome","volume":"5","author":"Andreani","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib37","doi-asserted-by":"crossref","first-page":"15574","DOI":"10.1038\/s41598-020-72467-9","article-title":"Complex genetic encoding of the hepatitis B virus on-drug persistence","volume":"10","author":"Thai","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jceh.2021.08.023_bib38","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.27894","article-title":"Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects","volume":"62","author":"Wong","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib39","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2014.01.044","article-title":"Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA","volume":"146","author":"Chan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.023_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jvh.12370","article-title":"Treating immune-tolerant hepatitis B","volume":"22","author":"Tseng","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jceh.2021.08.023_bib41","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2021.08.023_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vaccine.2017.11.027","article-title":"Status and progress of hepatitis B control through vaccination in the south-east Asia region, 1992-2015","volume":"36","author":"Childs","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.jceh.2021.08.023_bib43","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2021.08.023_bib44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2021.08.023_bib45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.inf.0000126412.93562.f5","article-title":"Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection","volume":"23","author":"Hom","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jceh.2021.08.023_bib46","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/jmv.24841","article-title":"Smaller reduction of hepatitis B virus DNA in liver tissue than in serum in patients losing HBeAg","volume":"89","author":"Tripodi","year":"2017","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.jceh.2021.08.023_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068152","article-title":"Suppression of HBV by tenofovir in HBV\/HIV coinfected patients: a systematic review and meta-analysis","volume":"8","author":"Price","year":"2013","journal-title":"PLos One"},{"key":"10.1016\/j.jceh.2021.08.023_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1377\/hlthaff.2008.0905","article-title":"A\u00a0simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective","volume":"30","author":"Post","year":"2011","journal-title":"Health Aff (Millwood)."},{"key":"10.1016\/j.jceh.2021.08.023_bib49","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5604\/01.3001.0009.8590","article-title":"Cost-effectiveness and clinical impact of antiviral strategies of HBeAg-positive and -negative chronic hepatitis B","volume":"16","author":"Oyag\u00fcez","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2021.08.023_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/cld.1125","article-title":"Chronic hepatitis B: challenges and successes in India","author":"Premkumar","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2021.08.023_bib52","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41467-019-10200-5","article-title":"Ciclopirox inhibits Hepatitis B Virus secretion by blocking capsid assembly","volume":"10","author":"Kang","year":"2019","journal-title":"Nat Commun"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688321002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:08:31Z","timestamp":1760854111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688321002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0973688321002292"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2021.08.023","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should We Treat Immune Tolerant Chronic Hepatitis B? Lessons from Asia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2021.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}